Acadia Pharmaceuticals reported third‑quarter 2025 revenue of $278.6 million, up 11 % from $250.4 million in the same quarter a year earlier and 5.5 % higher than the $264.6 million earned in Q2 2025. The growth was driven by a 12 % increase in NUPLAZID sales to $177.5 million and an 11 % rise in DAYBUE sales to $101.1 million, reflecting both volume gains and modest price adjustments.
NUPLAZID’s sales were supported by a 9 % volume increase and a 21 % rise in referrals, while DAYBUE benefited from an expanded field force and the launch of a named‑patient supply program outside the United States. The company shipped DAYBUE to more than 1,000 unique patients, including international customers, underscoring the product’s growing global footprint.
Acadia’s net income reached $71.8 million, or $0.42 per diluted share, a $0.28 beat over the consensus estimate of $0.14. The lift was largely attributable to a one‑time tax benefit from the “One Big Beautiful Bill Act,” which allowed immediate expensing of domestic R&D spending. After accounting for the tax benefit, adjusted EPS was $0.26, still well above expectations.
Operating expenses totaled $242.9 million, with research and development costs at $87.8 million and selling, general and administrative expenses at $133.4 million. The company maintained disciplined cost growth, keeping operating margin near 10 % despite higher R&D outlays for late‑stage pipeline candidates.
Cash, cash equivalents and investment securities stood at $847 million as of September 30, 2025, providing a strong liquidity buffer for commercial expansion and pipeline development.
Management raised its full‑year 2025 revenue outlook to $1.03–$1.095 billion, up from the prior guidance of $1.00–$1.05 billion, and lifted NUPLAZID net product sales guidance to $685–$695 million and DAYBUE guidance to $385–$400 million. CEO Catherine Owen Adams highlighted the company’s “strong commercial momentum” and confidence in achieving more than $1 billion in 2025 sales, while Chief Commercial Officer Thomas Garner emphasized the sustained demand for both products and the strategic importance of the pipeline.
Analysts noted the earnings beat and guidance raise as evidence of Acadia’s robust execution and market positioning, with the company’s EPS beat of $0.28 and revenue beat of $5.0 million underscoring its ability to generate cash flow while investing in future growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.